Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: ACTC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Advanced Cell Technology
www.advancedcell.com

Advanced Cell Technology is a biotechnology company focused on applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside.

Full Advanced Cell Technology profile here
Pdf

Advanced Cell Technology to be issued key Chinese IP patent for stem cell program

23rd Mar 2011, 10:58 am by Deborah Sterescu
ACT to receive key patent for stem cell program in China, allowing the company to enter the growing pharmaceutical market in the country ACT to receive key patent for stem cell program in China, allowing the company to enter the growing pharmaceutical market in the country

Advanced Cell Technology (OTCBB:ACTC) said Wednesday that it will be issued a Chinese intellectual property patent, covering the manufacturing of retinal cells from human embryonic stem cells.

The application for the Chinese patent provides broad coverage of the manufacturing of retinal pigment epithelial (RPE) cells, as well as methods for producing purified preparations of RPE cells from human embryonic stem cells, and the use of those cells in various compositions.

"The fact that we are being awarded a set of broad claims in China, following the issuance of the three far-reaching RPE patents in the U.S. last year, gives us greater confidence that we are in a position to create a dominant patent position around our stem cell-derived RPE program in leading markets around the world," said interim chairman and CEO Gary Rabin.

The company's stem cell-derived RPE program is being tested to replace those retinal cells in patients with degenerative eye diseases, such as Stargardt's, a juvenile eye condition. At the end of last year, the company received clearance from the US FDA to begin trials for Stargardt's, as well as Dry Age-Related Macular Degeneration.

The clinical program has already showed that these new eye cells can repair the visual function in animals models.

"This IP issuance is a particularly valuable step forward for us in Asia, as it could facilitate partnering and licensing arrangements," added Mr. Rabin.  

"This patent allowance is an indicator of what we hope to achieve in the IP realm in Europe and elsewhere."

Advanced Cell Technology's shares rallied 3.8% on Wednesday to $0.165 as of 10:43am EST.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.